Wells Fargo’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.44M | Buy |
68,765
+5,202
| +8% | +$117K | ﹤0.01% | 3517 |
|
|
2025
Q4 | $1.46M | Buy |
63,563
+38,615
| +155% | +$1.27M | ﹤0.01% | 3674 |
|
|
2025
Q3 | $750K | Buy |
24,948
+7,508
| +43% | +$225K | ﹤0.01% | 4010 |
|
|
2025
Q2 | $634K | Buy |
17,440
+171
| +1% | +$6.17K | ﹤0.01% | 3974 |
|
|
2025
Q1 | $625K | Sell |
17,269
-13,102
| -43% | -$545K | ﹤0.01% | 3929 |
|
|
2024
Q4 | $1.28M | Sell |
30,371
-2,886
| -9% | -$143K | ﹤0.01% | 3532 |
|
|
2024
Q3 | $1.85M | Buy |
33,257
+4,398
| +15% | +$224K | ﹤0.01% | 3107 |
|
|
2024
Q2 | $1.19M | Sell |
28,859
-2,549
| -8% | -$109K | ﹤0.01% | 3385 |
|
|
2024
Q1 | $1.47M | Sell |
31,408
-10,348
| -25% | -$488K | ﹤0.01% | 3201 |
|
|
2023
Q4 | $2M | Sell |
41,756
-19,217
| -32% | -$745K | ﹤0.01% | 2912 |
|
|
2023
Q3 | $2.17M | Buy |
60,973
+19,393
| +47% | +$768K | ﹤0.01% | 2748 |
|
|
2023
Q2 | $1.92M | Sell |
41,580
-74
| -0.2% | -$3.43K | ﹤0.01% | 2955 |
|
|
2023
Q1 | $1.67M | Buy |
41,654
+31,124
| +296% | +$1.34M | ﹤0.01% | 3015 |
|
|
2022
Q4 | $488K | Buy |
10,530
+2,482
| +31% | +$97.6K | ﹤0.01% | 3656 |
|
|
2022
Q3 | $333K | Sell |
8,048
-3,297
| -29% | -$169K | ﹤0.01% | 3935 |
|
|
2022
Q2 | $677K | Buy |
11,345
+6,061
| +115% | +$373K | ﹤0.01% | 3542 |
|
|
2022
Q1 | $383K | Buy |
5,284
+1,932
| +58% | +$134K | ﹤0.01% | 4590 |
|
|
2021
Q4 | $282K | Sell |
3,352
-2,196
| -40% | -$179K | ﹤0.01% | 5068 |
|
|
2021
Q3 | $500K | Sell |
5,548
-51,885
| -90% | -$4.69M | ﹤0.01% | 4661 |
|
|
2021
Q2 | $5.48M | Sell |
57,433
-16,433
| -22% | -$1.71M | ﹤0.01% | 2786 |
|
|
2021
Q1 | $8.41M | Sell |
73,866
-10,777
| -13% | -$1.47M | ﹤0.01% | 2337 |
|
|
2020
Q4 | $11.7M | Buy |
84,643
+43,404
| +105% | +$5.15M | ﹤0.01% | 1966 |
|
|
2020
Q3 | $3.39M | Sell |
41,239
-17,775
| -30% | -$1.47M | ﹤0.01% | 2863 |
|
|
2020
Q2 | $4.62M | Buy |
59,014
+24,075
| +69% | +$1.59M | ﹤0.01% | 2531 |
|
|
2020
Q1 | $1.55M | Sell |
34,939
-16,015
| -31% | -$832K | ﹤0.01% | 3225 |
|
|
2019
Q4 | $2.18M | Buy |
50,954
+12,348
| +32% | +$509K | ﹤0.01% | 3284 |
|
|
2019
Q3 | $1.65M | Sell |
38,606
-41,083
| -52% | -$2.23M | ﹤0.01% | 3487 |
|
|
2019
Q2 | $5.06M | Sell |
79,689
-1,597
| -2% | -$102K | ﹤0.01% | 2565 |
|
|
2019
Q1 | $5.64M | Buy |
81,286
+55,405
| +214% | +$3.17M | ﹤0.01% | 2444 |
|
|
2018
Q4 | $1.13M | Buy |
25,881
+2,139
| +9% | +$117K | ﹤0.01% | 3753 |
|
|
2018
Q3 | $1.81M | Buy |
23,742
+1,194
| +5% | +$97.1K | ﹤0.01% | 3500 |
|
|
2018
Q2 | $1.73M | Sell |
22,548
-1,652
| -7% | -$107K | ﹤0.01% | 3565 |
|
|
2018
Q1 | $1.23M | Buy |
24,200
+1,149
| +5% | +$57.9K | ﹤0.01% | 3746 |
|
|
2017
Q4 | $1.07M | Sell |
23,051
-23,793
| -51% | -$1.17M | ﹤0.01% | 3886 |
|
|
2017
Q3 | $2.49M | Sell |
46,844
-213,864
| -82% | -$12.7M | ﹤0.01% | 3133 |
|
|
2017
Q2 | $16.2M | Sell |
260,708
-301,682
| -54% | -$18.2M | 0.01% | 1529 |
|
|
2017
Q1 | $38.1M | Sell |
562,390
-202,304
| -26% | -$15.4M | 0.01% | 1002 |
|
|
2016
Q4 | $53.8M | Buy |
764,694
+28,887
| +4% | +$2.05M | 0.02% | 798 |
|
|
2016
Q3 | $52.2M | Sell |
735,807
-612,348
| -45% | -$39.1M | 0.02% | 764 |
|
|
2016
Q2 | $65.9M | Sell |
1,348,155
-380,807
| -22% | -$24.6M | 0.03% | 627 |
|
|
2016
Q1 | $109M | Sell |
1,728,962
-45,774
| -3% | -$3M | 0.04% | 440 |
|
|
2015
Q4 | $199M | Buy |
1,774,736
+219,746
| +14% | +$22M | 0.08% | 285 |
|
|
2015
Q3 | $150M | Buy |
1,554,990
+726,445
| +88% | +$83.2M | 0.06% | 335 |
|
|
2015
Q2 | $84.8M | Buy |
828,545
+817,444
| +7,364% | +$63.5M | 0.03% | 572 |
|
|
2015
Q1 | $690K | Buy |
11,101
+8,895
| +403% | +$494K | ﹤0.01% | 3755 |
|
|
2014
Q4 | $96K | Buy |
2,206
+1,585
| +255% | +$72.6K | ﹤0.01% | 4754 |
|
|
2014
Q3 | $35K | Sell |
621
-213
| -26% | -$10.7K | ﹤0.01% | 5070 |
|
|
2014
Q2 | $37K | Buy |
834
+408
| +96% | +$16.8K | ﹤0.01% | 5088 |
|
|
2014
Q1 | $21K | Buy |
+426
| New | +$21.9K | ﹤0.01% | 5209 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Wells Fargo's RARE Position: Q1 2026 in Review
Wells Fargo increased its Ultragenyx Pharmaceutical (RARE) stake by 8.2% in Q1 2026, buying an estimated $117K and bringing the position to 68,765 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3517.
Wells Fargo first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $199M in Q4 2015. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Wells Fargo held 68,765 shares of Ultragenyx Pharmaceutical worth $1.44M as of Q1 2026.
- Wells Fargo bought 5,202 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $117K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3517 holding.
- Wells Fargo first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
- Wells Fargo's Ultragenyx Pharmaceutical position peaked at $199M in Q4 2015.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.